Epigral Limited shares tumbled over 6% in morning trade on Monday after the company released its financial results for the quarter ended June 30, 2025 (Q1 FY26). As of 9:46 AM, the shares were trading 6.23% lower at Rs 1,834.40.
The integrated chemical manufacturer reported a revenue of ₹615 crore for Q1 FY26, marking a 6% year-on-year decline compared to ₹654 crore in the same quarter last year. The decline in topline was attributed to lower realizations and muted demand in select segments.
EBITDA for the quarter came in at ₹163 crore, down 7% YoY, though EBITDA margins remained steady at 27%. This was supported by continued operational efficiency and a stronger focus on product mix optimization.
Net profit stood at ₹160 crore, which includes a one-time deferred tax liability benefit of ₹81 crore. Adjusted for this item, profit after tax (PAT) was ₹79 crore—lower than the ₹86 crore reported in Q1 FY25.
On the operational front, plant utilization stood at 73% during the quarter. The company’s Return on Capital Employed (ROCE) improved to 24% from 21% a year ago, signaling improved profitability and capital efficiency.
In terms of financial strength, Epigral’s Net Debt-to-EBITDA ratio saw a significant improvement, dropping to 0.6x from 1.6x in the previous year—indicating a healthier balance sheet and reduced leverage.
The Derivatives & Specialty Chemicals segment remained a key contributor, accounting for 50% of the company’s total revenue in the quarter.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
